Department of Internal Medicine and Cardiology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum.
German Center for Cardiovascular Research (DZHK), Berlin, Partner Site, Germany.
Eur J Heart Fail. 2020 Mar;22(3):391-412. doi: 10.1002/ejhf.1741. Epub 2020 Mar 5.
Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF) remains a challenge. We recommend a new stepwise diagnostic process, the 'HFA-PEFF diagnostic algorithm'. Step 1 (P=Pre-test assessment) is typically performed in the ambulatory setting and includes assessment for heart failure symptoms and signs, typical clinical demographics (obesity, hypertension, diabetes mellitus, elderly, atrial fibrillation), and diagnostic laboratory tests, electrocardiogram, and echocardiography. In the absence of overt non-cardiac causes of breathlessness, HFpEF can be suspected if there is a normal left ventricular (LV) ejection fraction, no significant heart valve disease or cardiac ischaemia, and at least one typical risk factor. Elevated natriuretic peptides support, but normal levels do not exclude a diagnosis of HFpEF. The second step (E: Echocardiography and Natriuretic Peptide Score) requires comprehensive echocardiography and is typically performed by a cardiologist. Measures include mitral annular early diastolic velocity (e'), LV filling pressure estimated using E/e', left atrial volume index, LV mass index, LV relative wall thickness, tricuspid regurgitation velocity, LV global longitudinal systolic strain, and serum natriuretic peptide levels. Major (2 points) and Minor (1 point) criteria were defined from these measures. A score ≥5 points implies definite HFpEF; ≤1 point makes HFpEF unlikely. An intermediate score (2-4 points) implies diagnostic uncertainty, in which case Step 3 (F : Functional testing) is recommended with echocardiographic or invasive haemodynamic exercise stress tests. Step 4 (F : Final aetiology) is recommended to establish a possible specific cause of HFpEF or alternative explanations. Further research is needed for a better classification of HFpEF.
明确诊断射血分数保留的慢性心力衰竭(HFpEF)仍然具有挑战性。我们建议采用一种新的逐步诊断流程,即“HFpEF 诊断算法”。第 1 步(P=预测试评估)通常在门诊环境中进行,包括心力衰竭症状和体征评估、典型临床特征(肥胖、高血压、糖尿病、老年人、心房颤动)、诊断实验室检查、心电图和超声心动图。如果存在正常的左心室(LV)射血分数、无明显的心脏瓣膜疾病或心肌缺血,并且至少有一个典型的危险因素,但没有明显的非心源性呼吸困难的原因,则可怀疑 HFpEF。升高的利钠肽支持,但正常水平并不能排除 HFpEF 的诊断。第 2 步(E:超声心动图和利钠肽评分)需要进行全面的超声心动图检查,通常由心脏病专家进行。测量包括二尖瓣环早期舒张速度(e')、使用 E/e'估计的 LV 充盈压、左心房容积指数、LV 质量指数、LV 相对壁厚度、三尖瓣反流速度、LV 整体纵向收缩应变和血清利钠肽水平。这些测量值定义了主要(2 分)和次要(1 分)标准。得分≥5 分提示明确的 HFpEF;≤1 分提示 HFpEF 不太可能。中间得分(2-4 分)提示诊断不确定,建议进行第 3 步(F:功能测试),包括超声心动图或有创血流动力学运动应激试验。建议进行第 4 步(F:最终病因)以确定 HFpEF 的可能特定病因或替代解释。需要进一步研究以更好地对 HFpEF 进行分类。
Nat Rev Cardiol. 2025-6-22
J Am Heart Assoc. 2025-5-6